Index

AAH Pharmaceutical Ltd v Vantagemax 8
Abbott, F.M. 133, 226, 228
Abbott Laboratories 123, 132
Abraham, J. 126, 148
access to medicines see TRIPS Agreement, 2005 amendment to
Achilladelis, B. 115, 122, 124, 142
Advanta v Pioneer Hi-Bred International 386
AGFA 120
agriculture
changes in 250–53
food production, IPRs and 253–61
see also food security and intellectual property; geographical indications
Aguirre y Compañía SA v Paul Smith Ltd 10
Aguirre y Compañía SA v Smith Sport Optics, Inc. 11
Allen and Hanburys 125
American Cyanamid 115, 143
American Pharmaceutical Association (APA) 136–8
Anand, R. 165–6
anti-copying devices 39–41, 58, 70–72
antibiotics 111, 116, 124, 126–7, 132
international cartel 143–4, 150
penicillin 111, 115–16, 127, 142
streptomycin 116, 139–40, 141, 142
tetracycline 116, 143–4, 150
Argentina 258, 300
TRIPS Agreement, 2005 amendment to 224, 239, 243
Arsenal case 185–8
artistic works 26
Asprey case 8
Association of the British Pharmaceutical Industry (formerly Wholesale Druggists Trade Association) 148
AstraZeneca 127
Atari Games Corp. v Nintendo of America Inc. 101–2
Austen, R. 345
Austin, M. 132
Australia 43, 258, 287, 298, 380
authors
Central and Eastern Europe 208, 215, 216–20
moral rights 36, 45, 219–20
Aventis 121
Bainbridge 161
Baker v Selden 91–2
Banting, Frederick 140
Barnett, A. 357
Barr Pharmaceuticals 132
BASF 126, 137
‘Basmati’ 255, 272
Bayer 110, 111, 120, 121, 127
Barr Pharmaceuticals and 132
I.G. Farben 126
US properties 123
Bayh-Dole Act 1979 16
Beecham 126, 127, 128
Bell, R.H.V. 346
Bellecourt, Clyde 398
Benin 252
Benkler, Y. 78–9
Bensaude-Vincent, B. 112
Bently, L. 153
Berne Convention 37–8
Appendix 1971 37, 38, 43–4
compulsory licensing 37, 43–4
computer programs 26
educational exceptions from copyright 37, 43–9
moral rights 36
biodiversity
rights 29–30, 319, 381–2
rural communities and 345–7
see also bioprospecting; Cameroon;
food security and intellectual property; South Africa and biodiversity activities

biological assets of public research institutes 16, 20, 21, 23–4 
biopiracy 18 
bioprospecting 30, 319–20, 342–3 
access agreements 327–8 
associated national institutions 330–31 
contract, types of 329–30 
disputes and relevant law 341–2 
environmental impact assessments 331–2 
fees 329, 336 
grant of access 328 
intangible resources, transfer of 335 
IPRs 337–8 
IPRs, illegitimate 341 
monetary benefits 336–7 
monitoring activity 332–3, 338 
national competent authority 322 
ownership, transfer of 333–4 
PIC as foundation 327 
prior informed consent (PIC) 322–7 
resources, transfer of 333 
review of request 327–8 
sampling activities, authorised 329–30 
sellers 321–2 
tangible material, export of 334 
technology transfer and information 300, 336 
third parties, transfers to 339–40 
traditional knowledge 335 
unlawful acquisition of resources 340–41 
utility of accessed resources, potential 335–6 
see also Cameroon; South Africa and biodiversity activities 
biotechnology 
agriculture 251, 387–9 
pharmaceutical industry 124 
public research institutes 16, 20, 22
Black, James 115
Bliss, M. 140

Bonito Boats, Inc. v Thunder Craft Boats, Inc. 108 
book publishing 80 
Boots 116, 125 
Borlaug, Norman 370, 371, 376 
Bostick Ltd v Sellotape G.B. Ltd 181–2
Boylan, S.P. 209, 217 
Braithwaite, J. 143–4 
Brazil 255 
TRIPS Agreement, 2005 amendment to 224, 229, 231, 232, 236, 239, 243
Bristol and Hayden Chemical Corporation 143 
Bristol-Myers Squibb 119, 132–3 
broadband providers 83 
Brooks, Dexter 192–4 
Brown, William 370, 381 
browserwrap licences 106 
Brush, S. 377, 378 
‘Budweiser’ trade mark 289 
Burgener, M. 351, 352, 365 
Burroughs Wellcome 115, 116, 125 
Butler, W.E. 207 
Bynum, W.E. 111, 120
‘Café de Colombia’ 255 
Cambridge University 14–15 
Cameroon 344, 349, 365–6 
access to plant genetic materials 349–50 
bio-resources, exploitation of 350–51 
biochemical and biological diversity 347 
participation in decision-making 352 
Prunus africana 358–9 
recommendations 359–61 
traditional knowledge, loss of 347–8 
see also bioprospecting 
Canada 242, 258 
Canon KK v Metro-Goldwyn-Mayer Inc. 172, 183 
Castells, M. 82 
Castillo, Carlos Pérez del 234 
CD ROMs 26–7 
Central and Eastern Europe authors, rights of 208, 215, 216–20 
conclusion 221 
democratisation 206, 216–20 
‘developing’ countries 206, 208–11 
Guido Westkamp - 9781847208880 
Downloaded from Elgar Online at 02/14/2019 12:06:24PM via free access
Index

introduction 203–7
law in transition 211–14
new information regime 214–16
transition and development 207–11
CGIAR (Consulting Group on International Agricultural Research) 24, 379, 381, 382–3
Chain, Ernst 115
Chandler Jr., A.D. 123
Charles, D. 377
Chile 298, 300
China 257, 372
TRIPS Agreement, 2005 amendment to 224, 228, 229
Choi Hyuck 242, 243–4
Ciba 115, 121, 122, 128, 142
civil law systems and copyright 95, 220
Clarke, J. 347
clickwrap licences 105–6
Clinton, Bill 397
Cohen, J. 85
COKE ‘brand’ 200
Cole, P. 170
Colomer, Advocate General 185
common law systems
copyright 95
moral rights 220
communication systems and copyright
communicate, right to 74–6
conclusions 87
DRM technology and contractual licences 73, 74, 86–7
Internet 73–4, 80, 81, 82–4
Internet and control 84–7
introduction 73–4
mass communications, definition of 76
property rights 76–8, 81, 85
structure of systems 78–82
Community Registered designs 163–4, 166–7, 173
Community trade marks 10, 163
Compass Publishing BV v Compass Logistics 8–9
compulsory licensing
access to medicines and see TRIPS Agreement, 2005 amendment to APA (1919) 137
copyright and education 37, 43–4
Temporary National Economic Committee (1938–41)(US) 136
compilation see idea–expression dichotomy
software related invention 196
confidential information
patents and 25
public research institutes 20, 24–6, 29
Consulting Group on International Agricultural Research (CGIAR) 24, 379, 381, 382–3
Consumer Project on Technology (CPTech) 146, 226
contractual licences see licences, software rights 77
see also compulsory licensing
Cooper, M.H. 144
copyright
CD ROMs 26–7
communicate, right to 74–6
communication systems see communication systems and copyright
computer programs see computer programs
databases 27, 51, 174–5
democratic values 206, 216–20
educational needs see educational needs and copyright
European Union 203–4, 207
European Union Copyright Directive 39, 45, 54, 57, 70, 85, 104
expansion of 39–41, 54, 57–9, 69–72, 192, 193
human rights and 36, 52–3, 216
hypertext links to other sites 28
idea–expression dichotomy see idea–expression dichotomy
in rem right 75, 77–8
inexact infringement 167
Internet see Internet and copyright
knowledge, right to 52–3
limitations on 37–9
on-line materials 28
public research institutes 26–8
rationale for 35–7, 95–6
reform 53
repeated insubstantial takings 174–5

Guido Westkamp - 9781847208880
Downloaded from Elgar Online at 02/14/2019 12:06:24PM via free access
teaching materials 20
technological protection measures 39–41, 58, 70–72
transitional countries 203–4, 215, 216–20, 221
universities 20
video materials 27
see also growth of IPRs
copyright, ontological approach to 54–5, 72
circumvention of anti-copying devices 58, 70–72
copyright–patent dichotomy 61, 62, 66–7
German law 61, 63, 65, 67
idea–expression dichotomy 61, 64–7
modern copyright expansion 54, 57–9, 69–72
‘multilayer’ approach to legal reasoning 55–7
public communications 58, 63, 66–7, 68–9
public domain 61–2, 65–7
published and unpublished works 61–2
reproduction right 58, 62–3, 67–8, 70
three segments of copyright analysis 54, 59–61
Cornish, W. 153
Correa, C.M. 130, 131, 226
Côte d’Ivoire 303, 369
CPTech (Consumer Project on Technology) 146, 226
Cragg, G.M. 113
Crawhall, N. 352
creativity and IPRs 195–7
Cueni, Thomas 196
Cunningham, M. 359
Czech Republic 204, 212
databases 27, 51, 174–5
decompilation see under idea–expression dichotomy
democratisation and copyright principles 206, 216–20
Denmark 124
developing countries
access to medicines see TRIPS Agreement, 2005 amendment to
agriculture 251–3
biodiversity see biodiversity
collective management of licensing fees 49–51
educational needs see under educational needs and copyright
geographical indications 251–3, 254–5, 257, 258, 260–61, 302–4
special needs 209–11
transitional countries as 206, 208–11
utilitarian view on IP rights 137
see also bioprospecting; food security and intellectual property;
geographical indications and TRIPS Agreement; individual countries
‘digital agenda’ 38–9
WIPO Treaties 1996 39, 54, 85
digital rights management (DRM) technology and contractual licences 73, 74, 86–7
distance learning courses 20
Djerassi, Carl 118
Domagk, Gerhard 114
droit de suite 45
Du Pont 111
Duffin, J. 110
Dutfield, G. 380
ed educational needs and copyright
collective management of licensing fees 49–51
developing countries 42–3, 49–51
digital usage 41–2
educational exceptions 43–9
knowledge, right to 52–3
levy system 51
technological developments 51–2
technological protection measures (TPMs) 39–41
Egypt 229
Ehrlich, Paul 110, 111, 114, 120
Eisenberg, D.M. 346
Elion, Gertrude 123, 140, 141
Elion, Gertrude 115
email 80, 83–4, 86–7
employees
public research institutes 19–21
Guido Westkamp - 9781847208880
Index

trade secrets and former 25
Engelberg, A.B. 145–6
equipment and tools of public research institutes 20–21, 24, 31
Ethiopia 252
European Commission and public research institutes 15, 16, 22
European Court of Justice
‘feta’ cheese 283–5
geographical indications 280
trade marks 8, 12, 172, 183–8
European Federation of Pharmaceutical Industries and Associations (EFPIA) 134–5, 153, 235
European Technology Assessment Network (ETAN) 201
European Union
copyright 203–4, 207
decompilation of computer programs 94, 100, 104, 106
see also geographical indications in EU; geographical indications and TRIPS Agreement; TRIPS Agreement, 2005 amendment to
European Union Directives
computer programs 95
database rights 51, 174–5
electronic commerce 84
information society/copyright 39, 45, 54, 57, 70, 85, 104
software 94, 100, 106
trade marks 11, 183
European Union Regulations
Community Design 163–4, 166–7, 173
Community trade mark 11, 163
geographical indications see geographical indications in EU
medicinal products 153
Fairley, P. 125
Farben, I.G. 114, 121, 126
Farnsworth, N. 112
Ferrari S.p.A. Esercizio Fabbriche Automobili E Corse v Roberts 179–80
fertilisers, chemical 371–2
‘feta’ cheese 283–5, 298
films 26
Fishbein, M. 141
Fleming, Alexander 115
Florey, Howard 115–16
Florida State University 398
Fomete, T. 347
food security and intellectual property 369, 390
biotechnologies and conservation goals 387–9
Consultative Group on International Agricultural Research (CGIAR) 24, 379, 381, 382–3
genetic erosion 373–9
Green Revolution 370–73
hybrids, creation of 370
patents 24, 386, 387, 388
private sector research, shift to 385–6
UN Food and Agriculture Organization (FAO) initiatives 379–84
Fowler, C. 375, 381
France
copyright 95, 220
geographical indications 265, 267, 278, 284
pharmaceutical industry 114, 151
‘sincere information’ 168
Frankel 374
Frost, G.E. 143
Gabon 303
Gadsden, Henry 119
Geigy 115, 121–2, 128
generic drug companies 119, 132, 133, 150, 153, 154, 248
lobbying power 145
McKesson and Robbins 144
partnership initiatives 249
utilitarian view on IP rights 137
see also TRIPS Agreement, 2005 amendment to
genetic erosion 373–9
genetic material
biodiversity rights 29–30, 319, 381–2
public research institutes 16, 20, 21, 23–4, 29–31
rural communities 345–7
see also bioprospecting; Cameroon; South Africa and biodiversity activities

Guido Westkamp - 9781847208880
Downloaded from Elgar Online at 02/14/2019 12:06:24PM via free access
geographical indications (GIs)
agriculture, changes in 250–53
agriculture and food production, role
of IPRs in 253–61
developing countries 251–3, 254–5, 257, 258, 260–61, 302–4
international protection for, rise of 265–9
provenance of 262–4
regional protection by EU see geographical indications in EU
traditional knowledge 255, 297–8, 302–3, 318
TRIPS Agreement see geographical indications and TRIPS
Agreement
geographical indications in EU 274–5
amended Regulation 295–6
definition of GIs, disputes over 281–2
foreign GIs 255, 266
generic indications 282–6
protected designation of origin (PDO) 276
protected geographical indication (PGI) 276
registration procedure 276–7, 295
rights conferred 277–8
trade mark conflicts 279–80
WTO ruling on GIs and trade marks 255, 287–94
geographical indications and TRIPS Agreement 253–4, 263
coeexistence of GIs and trade marks 290–92
development-friendly 302–3
different views on protection of GIs 255–61, 269–70
exception to trade mark rights, GIs as 293–4
exceptions from obligations 273–4, 285–6
generic names 285–6
handicrafts, traditional 272–3
market access, closing off 286, 305
multilateral register, proposed 299–302
other foodstuffs 272–3
priority, earlier trade mark owners’ rights of 292–3
subject matter, proposed extension of eligible 297–9
trade marks and 279–80, 287–94
way forward 303–6
wines and spirits, enhanced protection for 270–72, 303
WTO ruling, EU Regulation amended after 295–6
WTO ruling on GIs and trade marks 255, 287–94
Germany 268, 284
authors, rights of 61, 63, 65
copyright 67, 95, 220
patent law 111, 151–2, 160
pharmaceutical industry 110, 120–21, 124, 125, 126–7, 128, 131
unfair competition 175
Gerolsteiner Brunnen GmbH & Co. v Putsch GmbH 280, 288–9, 292
Glaxo 116, 125, 126
GlaxoSmithKline 119, 127
Goodman, J. 119, 132
goodwill 174–5
Grace, O.M. 348
Graham, R.A. 358
Granstrand, O. 132
Greece and ‘feta’ cheese 283–5, 298
Green Revolution 370–73
Greenberg, A.S. 123
Greyhound Corp. v Both Worlds, Inc. 396
Groom 165
growth of IPRs 191–2, 202
fact and nature of 191–2, 193
fear and uncertainty 201
innovation and creativity, impact on 195–7
judiciary 197
lobbying 192, 201
management matter 198–9
public interest 194
ratchet effect 192–4
small and medium-sized enterprises (SMEs) 197–8
‘stacking and layering’ 199–201
Guatemala 298
Hamilton, M.A. 217
Hancher, L. 151
Levin, R.C. 130
Levinstein, Ivan 147
licences, software
browserwrap 106
categorisation as a sale 106
clickwrap 105–6
compilation, prevention of 105–7
DRM technology and contractual 73, 74, 86–7
shrinkwrap 105
licensing and patents, compulsory see compulsory licensing
Liebenau, J. 122, 125
lifestyle drugs 119
literary works
computer programs 26, 28
digital technology 82–3
universities 20
Love, James 226
LTJ Diffusion v Sadas 8, 9
McCrum v Eiser 92
Macdonald, S. 191, 195–6, 197, 198, 200, 201, 202
McKesson and Robbins 144
Madagascar 303
Madey v Duke University 20–21
Maffi, L. 348
Malawi 252
Mandela, Nelson 225
Mann, C.C. 110, 121
Mann, J. 115
Mansfield, E. 130
Marca Mode CV v Adidas AG & Adidas Benelux BV 183
Martini, M.L. 374
Massachusetts, University of 397
Mastercrafters Clock & Radio Co. v Vacheron Constantin – Le Coultre Watches 179
Maverty Media Group Ltd, In re 395
May and Baker 114, 115, 125, 126
Médecins Sans Frontières 226, 247
medicines, access to see TRIPS
Agreement, 2005 amendment to
medicines, plant-based 112–13, 352–8, 358–9
Menon, Vanu Gopala 232
Merck 115, 119, 121, 123, 126, 127
cortisone 117
penicillin 116
strategic IP policies 142
streptomycin and patents 141
vitamin B12 and patents 139
Merges, R.P. 138–9
Merrell Dow v HN Norton 131
Mexico 370
mineral water and geographical indications 279–80, 305
Mooney, P. 375
Mooney, P.R. 345
moral rights 36, 45, 219–20
Motta, Eduardo Perez 230–31
Mowery, D.C. 123, 124
MSF 226, 247
Mulford and Co., H.K. 138
Musa, T. 345
musical works 26
digital technology 82–3
‘sampling’ 174
Musker 166–7
Nastelski, K. 152
national emblems 188
National Health Service 148, 150–51
Native American names
conclusions 406
disparaging trade marks 395–6, 401–3
Harjo v Pro-Football Inc, 399–405
Hines, In re two-part test 402, 403
introduction 391, 396–9
laches defence 404–5
merchandise sales 397–8
scandalous trade marks 392–5, 401
Ndii, M. 358
N’Diaye, N. 210–11
Netanel, N.W. 218–19
Netherlands 41
networks, peer-to-peer 84, 85, 86–7
New Zealand 43
Newcity, M.A. 215
Nguffo, S. 360
Nicholas, George 126
Nichols case 5
Nicholson, Denise 50–51
Nigeria 297
Nimmer, M. 346
Nkodo, K. 346
Noble, D.F. 123

Guido Westkamp - 9781847208880
Downloaded from Elgar Online at 02/14/2019 12:06:24PM
via free access
Northern Foods Plc v DEFRA 281–2
Novartis 122

Okediji, R. 38
Oklahoma, University of 396–7
on-line materials 28
Owen, G. 126
Owens, L. 136

Parke Davis and Co. 123, 138, 143
passing off 171, 174, 180–83, 185, 187
Pasteur, Louis 110
patents
access to medicines see TRIPS Agreement, 2005 amendment to
applications by public research institutes 33
applications for 3–4 compulsory licensing see compulsory licensing
confidential information and 25 continental Europe 151–3
corporate assets 198–9
corporate assets 151
France 114, 151
Germany 111, 151–2, 160
inexact infringement 167
innovation and creativity, impact on 195–7
Italy 152
multiple claims 161
natural substances 111–12
plant-related 24, 386, 387, 388
repeated insubstantial takings 174–5
sonar case 168–70, 173
Switzerland 151
synthetic chemistry in Germany 111
synthetic versions of natural substances 112
UK legislation 147, 149–50, 151
UK pharmaceutical industry 146–51
unity of creation 164
universities 15
US design 164
see also growth of IPRs
patents in US pharmaceutical industry 135–46
disclosure of patents, inadequate 136–7
ethical and over-the-counter drugs
141–2
generic manufacturers 144, 145
Hatch–Waxman Act 1984 144–6, 155
international antibiotics cartel 143–4
licensing, compulsory 136, 137
licensing, restricted 142–3
lobbying power 145, 146
natural substances 138–41, 142
pressure groups 146
price-reducing competition 142
Senate Subcommittee inquiry (1959–1962) 144
strategy, corporate IP 142–4
utilitarian viewpoint 137
peer-to-peer networks 84, 85, 86–7
penicillin 111, 115–16, 127, 142
Peris, I. 164
Peru 239
pesticides 371–2
Pfizer 116, 142, 143, 144, 150
pharmaceutical industry
access to medicines see TRIPS Agreement, 2005 amendment to
acquisitions and mergers 1989–2000 129
conclusions 153–5
drug discovery in twentieth century 113–19
generic drug companies see generic drug companies
patents in continental Europe and 114, 151–3
patents, importance of 129–35
patents in UK and 146–51
patents in US and see patents in US pharmaceutical industry
present day 128–9
propagandizing 133–5
research-based industries, growth of 119–27
scientific foundations of 109–13
strategic use of patents and trade marks 130–33
trade marks 119, 130, 132–3, 137, 154, 200
Pharmaceutical Research and Manufacturers of America (PhRMA) (previously
Index

Pharmaceutical Manufacturers Association, PMA 130, 134, 135, 145, 235, 246
Philippines 239, 243
Pierce, Frederick 110
Pistor, K. 213
plant varieties
Community 167
universities 20
see also food security and intellectual property
plant-based medicines 112–13, 352–8, 358–9
Ploman, E.W. 208, 215, 216, 218
Plotkin, M.J. 112
Poland 204, 212
Polaroid v Kodak 197
Porter 109, 111, 120
post sale effects of trade marks
Arsenal case 185–8
European Court of Justice 183–8
introduction 176
national emblems 188
passing off 171, 174, 180–83, 185, 187
United Kingdom 176–7
United States 178–80
postgraduate students 21
Poulec Frères 125
Principe, P. 112
property rights
copyright 35–7, 58–9, 76–8, 81, 85
Proskowetz, E.R. von 374
Prunus africana 358–9
Public Citizen 130, 146
public research institutes
audit, IP 16–17, 22–3, 34
basic research 15
biodiversity rights 29–30
biological assets 16, 20, 21, 23–4
copyright 26–8
databases 27
equipment and tools 20–21, 24, 28, 31
entrepreneurial activity 20, 21, 23–4
management, IP 31–4
non-staff 21
ownership and control of IP 17–21
patents 15, 25, 33
policy on IP 21–30
postgraduate students 21
staff 19–21, 25
third-party contracts 22
third-party IP 30–31
trade marks 25, 28
Quaker UN Office 226
Qualitex v Jacobson 194
radio 79–80
Redskins case, Washington see Native American names
Reed Executive Plc v Reed Business Information Ltd 8, 9
registered rights
inexact infringement 167
introduction 160–61
multiple claims, impact of 168–73
multiple claims and series registrations 161–4
repeated insubstantial takings 174–5
seabird trade marks case 170–72, 173, 174
sonar patent case 168–70, 173
unity of creation 164–7
Reichman, J. 226
reverse engineering see under idea–expression dichotomy
Rhône-Poulec/May and Baker 115, 121, 126, 128
Ricketson, S. 38, 44, 47–8
Rivette, K.G. 132
Robertson 174
Roe, J.E. 123
Rollins, A.D. 131
Rugby Football Union v Cotton Traders Ltd 188
Russia 207, 211, 214, 215
Rutgers University 141
San communities and Hoodia 352–8
Sandoz 115, 121, 122
Sargent, Charles 148
Saro-Wiwa, Ken 219
Guido Westkamp - 9781847208880
Downloaded from Elgar Online at 02/14/2019 12:06:24PM via free access
Satchell, R.D. 149
Schindler, Franz 374
Schumacher, Thomas 194
seabird trade marks case 170–72, 173, 174
Sega Enterprises Ltd v Accolade, Inc. 102
Sen, A. 209
shrinkwrap licences 105
Slinn, J. 124, 125, 128, 130
Smale, M. 376, 378–9
small to medium-sized enterprises (SMEs) 197–8, 254, 257
Smith, Jerome 248
Smith, Kline and French 115
Smith as a trade mark 4–12
Smithkline Beckman Corp. v Pennex Products Co. 180
Sneader, W. 114, 118, 141, 143
Sockalexis, Louis 398
Sodastream Ltd v Thorn Cascade Co. Ltd 182–3
sonar patent case 168–70, 173
Sony Computer Entertainment v Connectix 102–3
Sotorock Holding Ltd v L.E. Gordon and G. Gordon 10–11
sound recordings 26
South Africa
access to medicines 224–5
generic drug manufacturers 248
TRIPS Agreement 229, 232, 236, 297
South Africa and biodiversity activities 344, 349, 365–6
access to bio-materials 351–2
biological and cultural diversity 348
participation in decision-making 352, 356–8
recommendations 361–5
San traditional knowledge, exploitation of 352–8
see also bioprospecting
Squibb 116, 123, 127, 143
Sri Lanka 239
Standford University 397
Steele, H. 142
Steen, K. 123
Stephenson Jr, D.J. 352
Sterling Drug 123
steroids 117, 127
Stewart, F.C. 137
Stolz, R. 120
Stone, T. 110
Sullivan 199
sulphonamide drugs 111, 114–15, 124
Swaminathan, M.S. 370–71
Switzerland 121–2, 124, 126, 128, 151
TRIPS Agreement 241, 242, 269–70
Tansey, Geoff 226
teaching materials 20
technological protection measures (TPMs) 39–41, 58, 70–72
technology transfers 300, 336
see also bioprospecting
Teddy Smith SA v JLB Marketing Inc. 10
Teece, D. 197
Teitel, R. 212, 213
television 76, 79–80
telemetry 76, 79–80
Temin, P. 116, 141, 142, 144
Thailand 229
Thomas, D.W. 347
Thomas, L.G. 111, 127
Tichane, D.M. 176
Tonye, M.M. 358
Tootal 160
Toronto, University of 140–41
trade marks
Community 10, 163
confidential information and 25
expansion of 194
geographical indications and 279–80, 287–94
infringement of 6–12
Madrid Protocol 163
multiple claims and series registrations 161–3
Native American names and see Native American names
pharmaceutical industry 119, 130, 132–3, 137, 154
post sale effects see post sale effects of trade marks
public research institutes 28
seabird case see seabird case 170–72, 173, 174
Smith 4–12
traditional knowledge 318
unity of creation 164–6

Guido Westkamp - 9781847208880
Downloaded from Elgar Online at 02/14/2019 12:06:24PM
via free access
see also growth of IPRs

traditional knowledge
bioprospecting 335
rural communities and 345–7, 347–8
San communities 352–8
see also Cameroon; South Africa and biodiversity activities

traditional knowledge and intellectual property 309
community and resources 316–17
creativity and traditional practices 310–11
ethical ‘value’ 317–18
geographical indications 255, 297–8, 302–3, 318
narration of culture 311–14, 317–18
public goods 315–16
trade marks 318
trade relations 314–15
‘value adding’ IP 310

transitional countries see Central and Eastern Europe

TRIPS Agreement 26, 36, 37–8, 201, 247–8
computer programs 26
confidentiality of test data 25–6
democratic values 217–19
’digital agenda’ 38–9
educational exceptions from copyright 44–9
geographical indications see geographical indications and TRIPS Agreement
idea–expression dichotomy 94
judiciary 197
moral rights not included 36
pharmaceutical industry 135, 155
principles and objectives 52
transitional countries 203, 205, 207

TRIPS Agreement, 2005 amendment to 243–6
30 August 2003 Chairman’s Statement 234
30 August 2003 Decision 232–6
African, Caribbean and Pacific (ACP) states 232
African Group 229–30, 236, 238–40, 241–2, 244
Chairman’s draft (December 2002) 230–31
Chairman’s Statement, status of 237–40, 244
Council meeting (June 2005) 241–2
Council meeting (October 2005) 243
deadline for acceptance 223
developed country position 241, 242
developing country position 229–30, 243, 249
Doha Declaration 225–6
domestic use and compulsory licensing, issue of 223–4, 225–6
European Union compromise text 231–2
European Union position 226, 227–9, 231–2, 235, 241, 242
introduction 222–3
labelling and packaging 229, 234, 240, 244
NGOs 226–7, 228, 231, 235, 247, 248, 249
paragraph 6 negotiations 226–36
paragraph 11 negotiations 236–47
range of parties involved 248–9
reactions to 246–7
South Africa 224–5
United States position 226, 227–9, 231, 232, 235, 241, 242, 243
Turkey 297
Twarog, S. 348
Two Pesos v Taco Cabana 194

UN Food and Agriculture Organization (FAO) initiatives 379–84
UNAIDS 249
unfair competition 174–5, 187, 303–4
UNICEF 249
United Kingdom
copyright, expansion of 192, 193
‘feta’ cheese 284
idea–expression dichotomy, development of 90–91, 92–3, 94
inexact infringement 167
moral rights 36
originality, rule on 93
patent legislation 147, 149–50, 151
pharmaceutical industry 111, 114, 115–16, 118, 124–7, 128, 131, 200

Guido Westkamp - 9781847208880
Downloaded from Elgar Online at 02/14/2019 12:06:24PM via free access
Index

pharmaceutical industry, patents in 146–51
plant breeding research 385
plant genetic resources 380
sonar patent case 168–70, 173
trade mark legislation 12
trade mark series and ‘association’ 162–3
trade marks case, seabird 170–72, 173, 174
trade marks, post sale effects of 176–7
trade marks and unity of creation 164–6
unfair competition 174–5
United States
  ‘Basmati’ 255
design patents 164
  DMCA 1998 54, 99–100, 104–5
drug safety testing 115
‘fair use’ 48, 89, 101–3
idea–expression dichotomy, development of 90, 91–2, 93–4
inexact infringement 167
‘merger’ doctrine 90, 92
moral rights 36, 220
Native American names and trade marks see Native American names
patents see patents in US pharmaceutical industry
performing rights case 45–6
pharmaceutical industry see United States, pharmaceutical industry in
plant breeding research 385
plant genetic resources 380
trade mark and patent registrations 200
trade marks 133, 137, 162, 178–80, 194, 200
TRIPS Agreement see under TRIPS Agreement, 2005 amendment to
WIPO Treaties, implementation of 39, 85
see also geographical indications and TRIPS Agreement
United States, pharmaceutical industry in 122–4, 126, 128, 131, 134
development, cost of drug 129–30
natural product research 111
new drugs, decline in 118
patents see patents in US pharmaceutical industry
penicillin 116
research funding 119, 123–4
safety of drugs 115
steroids 117
tablet form 125
trade marks 132–3, 137
universities see public research institutes
Upjohn 143
Vavilov, N.I. 374
video materials 27
Viennetta case 176–7
Vögele, Jurgen 372
Waksman, Selman 141
Wall, Monroe 132
Wallace, Henry A. 370
Wani, Mansukh 132
Washburn, J. 146
Weatherall, M. 114, 115, 141
Wellcome 125, 126, 127, 128
Wells, M.D. 346
Wengenroth, U. 120
Werth, B. 117, 119
Weston 161
Whitaker, Rosa 227, 228
White, A. 356
White v Samsung 194
WHO 249
Wimmer, W. 111
WIPO (World Intellectual Property Organization) 45
TRIPS Agreement 249
Wisconsin, University of 140
World Wide Web 83, 84, 85, 86–7
Wyeth Pharmaceuticals 14
Wyk, B. van 356
Wynberg, R. 356, 357
Zambia 239
Zeneca 127